Your browser doesn't support javascript.
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.
Benson, Merrill D; Buxbaum, Joel N; Eisenberg, David S; Merlini, Giampaolo; Saraiva, Maria J M; Sekijima, Yoshiki; Sipe, Jean D; Westermark, Per.
  • Benson MD; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Buxbaum JN; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
  • Eisenberg DS; Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, USA.
  • Merlini G; Amyloid Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, and University of Pavia, Pavia, Italy.
  • Saraiva MJM; Institute of Molecular and Cellular Biology, University of Porto, Molecular Neurobiology, Porto, Portugal.
  • Sekijima Y; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
  • Sipe JD; Department of Biochemistry (Retired), Boston University School of Medicine, Boston, MA, USA.
  • Westermark P; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Amyloid ; 27(4): 217-222, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-889371
ABSTRACT
The ISA Nomenclature Committee met electronically before and directly after the XVII ISA International Symposium on Amyloidosis, which, unfortunately, had to be virtual in September 2020 due to the ongoing COVID-19 pandemic instead of a planned meeting in Tarragona in March. In addition to confirmation of basic nomenclature, several additional concepts were discussed, which are used in scientific amyloid literature. Among such concepts are cytotoxic oligomers, protofibrils, primary and secondary nucleation, seeding and cross-seeding, amyloid signature proteins, and amyloid plaques. Recommendations for their use are given. Definitions of amyloid and amyloidosis are confirmed. Possible novel human amyloid fibril proteins, appearing as 'classical' in vivo amyloid, were discussed. It was decided to include fibulin-like extracellular matrix protein 1 (amyloid protein AEFEMP1), which appears as localised amyloid in portal veins. There are several possible amyloid proteins under investigation, and these are included in a new Table.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Amyloidogenic Proteins / Amyloid / Amyloidosis / Terminology as Topic Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Amyloid Journal subject: Biochemistry Year: 2020 Document Type: Article Affiliation country: 13506129.2020.1835263

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Amyloidogenic Proteins / Amyloid / Amyloidosis / Terminology as Topic Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Amyloid Journal subject: Biochemistry Year: 2020 Document Type: Article Affiliation country: 13506129.2020.1835263